PARP1 and cancer: The term “BRCAness” was coined to described non-germline BRCA1 or BRCA2 mutant cancers that share the phenotypic characteristics of selective therapeutic vulnerability to PARP inhibition due to deficiency of other key proteins involved in HRR, such as RAD51, RAD54, ATM, ATR, NBS1, PALB2, and the FANC gene family [23].